Pertral 50 mg
Contraindications: Hypersensitivity to sertraline. MAOI use within 14 days (concurrently or within 14 days of stopping an MAOI or sertraline). Concurrent use of oral concentrate (contains alcohol) with disulfiram. Concurrent use with pimozide; initiation in pts treated with linezolid or methylene blue.Pregnancy/Lactation: Unknown if drug crosses placenta or is distributed in breast milk. Children: Children and adolescents are at increased risk for suicidal ideation and behavior or worsening of depression esp. during the first few mos of therapy. Elderly: No age-related precautions noted but lower initial dosages recommended.
Treatment of major depressive disorders panic disorder obsessive-compulsive
disorder (OCD) post-traumatic stress disorder (PTSD) premenstrual dysphoric
disorder (PMDD) social anxiety disorder. OFF-LABEL: Eating disorders
bulimia nervosa generalized anxiety disorder (GAD).
Frequent (26%?12%): Headache nausea diarrhea insomnia drowsiness
dizziness fatigue rash dry mouth. Occasional (6%?4%): Anxiety
nervousness agitation tremor dyspepsia diaphoresis vomiting constipation
sexual dysfunction visual disturbances altered taste. Rare (Less Than 3%):
Flatulence urinary frequency paresthesia hot flashes chills.
Adverse effects/toxic reactions
Serotonin syndrome (seizures arrhythmias high fever) neuroleptic malignant
syndrome (muscle rigidity cognitive changes) suicidal ideation have occurred.
Seizure disorder hepatic impairment pts at risk for uric acid nephropathy
elderly pts pts in third trimester of pregnancy pts at high risk for suicide family
history of bipolar disorder or mania pts with risk factors for QT prolongation
(e.g. hypokalemia hypomagnesemia) alcoholism. Pts in whom weight loss is